{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:49:18Z","timestamp":1775101758249,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["20S11906200"],"award-info":[{"award-number":["20S11906200"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104240"],"award-info":[{"award-number":["82104240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX09711002-014-004"],"award-info":[{"award-number":["2018ZX09711002-014-004"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bmc.2025.118259","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:26:18Z","timestamp":1747941978000},"page":"118259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability"],"prefix":"10.1016","volume":"128","author":[{"given":"Yurong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118259_b0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2021.05.007","article-title":"Anti-HBV therapeutic potential of small molecule 3, 5, 6, 7, 3\u2032, 4\u2032-Hexamethoxyflavone in vitro and in vivo","volume":"560","author":"Tan","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2025.118259_b0010","article-title":"siRNA drug development against hepatitis B virus infection","volume":"1","author":"Flisiak","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bmc.2025.118259_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115128","article-title":"Overview of the development of HBV small molecule inhibitors","volume":"249","author":"Yang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118259_b0020","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (\u2212) \u03b2-l-2\u2032, 3\u2032-dideoxy-3\u2032-thiacytidine","volume":"42","author":"King","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2025.118259_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1128807","article-title":"The progress of molecules and strategies for the treatment of HBV infection","volume":"13","author":"Pan","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.bmc.2025.118259_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4722047","article-title":"Hepatitis B: model systems and therapeutic approaches","volume":"2024","author":"Yu","year":"2024","journal-title":"J Immunol Res"},{"key":"10.1016\/j.bmc.2025.118259_b0035","article-title":"Role of epigenetic modification in interferon treatment of hepatitis B virus infection","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2025.118259_b0040","first-page":"935","article-title":"Aiming for functional cure with established and novel therapies for chronic hepatitis B, Hepatology","volume":"6","author":"Choi","year":"2022","journal-title":"Communications"},{"key":"10.1016\/j.bmc.2025.118259_b0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4254\/wjh.v15.i5.585","article-title":"Current and novel modalities for management of chronic hepatitis B infection","volume":"15","author":"Salama","year":"2023","journal-title":"World J Hepatol"},{"key":"10.1016\/j.bmc.2025.118259_b0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/jvh.13926","article-title":"Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos (t) ide analogues therapy","volume":"31","author":"Wu","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bmc.2025.118259_b0055","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/microorganisms11112622","article-title":"Phylogenetic analysis and emerging drug resistance against different nucleoside analogues in hepatitis b virus positive patients","volume":"11","author":"Gohar","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.bmc.2025.118259_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-3099(07)70264-5","article-title":"Therapeutic strategies in the management of patients with chronic hepatitis B virus infection","volume":"8","author":"Papatheodoridis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2025.118259_b0065","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/v15112241","article-title":"Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis","volume":"15","author":"Henriquez-Camacho","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2025.118259_b0070","article-title":"Kushenin combined with adefovir dipivoxil or entecavir for chronic hepatitis b: a systematic review and meta\u2010analysis","volume":"2021","author":"Liao","year":"2021","journal-title":"Evid\u2010Based Compl Altern Med"},{"key":"10.1016\/j.bmc.2025.118259_b0075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11655-020-3250-0","article-title":"Adefovir dipivoxil plus Chinese medicine in HBeAg-positive chronic hepatitis B patients: a randomized controlled 48-week trial","volume":"26","author":"Li","year":"2020","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.bmc.2025.118259_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-\u03b1 to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathogens"},{"key":"10.1016\/j.bmc.2025.118259_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2014.04.004","article-title":"Immunotherapeutic interventions in chronic hepatitis B virus infection: a review","volume":"407","author":"Wang","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bmc.2025.118259_b0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2014.01.046","article-title":"A review of non-nucleoside anti-hepatitis B virus agents","volume":"75","author":"Zhang","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118259_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223062","article-title":"IFN-\u03b1 induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2025.118259_b0100","doi-asserted-by":"crossref","unstructured":"Lyu W, Qin H, Li Q, Lu D, Shi C, Zhao K, Zhang S, Yu R, Zhang H, Zhou X, Xia S, Zhang L, Wang X, Chi X, Liu Z. Novel mechanistic insights - A brand new Era for anti-HBV drugs. Eur J Med Chem 2024;279:116854. doi: 10.1016\/j.ejmech.2024.116854. Epub 2024 Sep 13. PMID: 39276582.","DOI":"10.1016\/j.ejmech.2024.116854"},{"key":"10.1016\/j.bmc.2025.118259_b0105","doi-asserted-by":"crossref","unstructured":"Hui RW, Mak LY, Fung J, Seto WK, Yuen MF. Prospect of emerging treatments for hepatitis B virus functional cure. Clin Mol Hepatol. 2025 Feb;31(Suppl):S165-181. doi: 10.3350\/cmh.2024.0855. Epub 2024 Nov 14. PMID: 39541952; PMCID: PMC11925432.","DOI":"10.3350\/cmh.2024.0855"},{"key":"10.1016\/j.bmc.2025.118259_b0110","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/v15122395","article-title":"Gene-editing and RNA interference in treating hepatitis B: a review","volume":"15","author":"Kasianchuk","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2025.118259_b0115","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene editing technologies to target HBV cccDNA","volume":"14","author":"Martinez","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2025.118259_b0120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2025.118259_b0125","doi-asserted-by":"crossref","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Luki\u0107 T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D; B-Clear Study Group. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med. 2022 Nov 24;387(21):1957-1968. doi: 10.1056\/NEJMoa2210027. Epub 2022 Nov 8. PMID: 36346079.","DOI":"10.1056\/NEJMoa2210027"},{"key":"10.1016\/j.bmc.2025.118259_b0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/microorganisms12030599","article-title":"RNA interference therapeutics for chronic hepatitis B: progress, challenges, and future prospects","volume":"12","author":"Sneller","year":"2024","journal-title":"Microorganisms."},{"key":"10.1016\/j.bmc.2025.118259_b0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11262-024-02105-3","article-title":"Tackling hepatitis B Virus with CRISPR\/Cas9: advances, challenges, and delivery strategies","volume":"60","author":"Nair","year":"2024","journal-title":"Virus Genes"},{"key":"10.1016\/j.bmc.2025.118259_b0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molmed.2023.10.005","article-title":"Three 'E' challenges for siRNA drug development","volume":"30","author":"Guo","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bmc.2025.118259_b0145","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.bmc.2025.118259_b0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","article-title":"Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors","volume":"5","author":"Zhang","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2025.118259_b0155","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acsinfecdis.8b00337","article-title":"Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives","volume":"5","author":"Yang","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2025.118259_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115485","article-title":"A prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B","volume":"257","author":"Chen","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118259_b0165","doi-asserted-by":"crossref","first-page":"21126","DOI":"10.1021\/acs.jmedchem.4c01814","article-title":"The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075","volume":"67","author":"Vendeville","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118259_b0170","doi-asserted-by":"crossref","unstructured":"Lee HL, Jang JW. Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on \u201cPhase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients\u201d. Clin Mol Hepatol. 2024 Oct;30(4):692-694. doi: 10.3350\/cmh.2024.0346. Epub 2024 May 14. PMID: 38741237; PMCID: PMC11540340.","DOI":"10.3350\/cmh.2024.0346"},{"key":"10.1016\/j.bmc.2025.118259_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105715","article-title":"A novel hepatitis B virus capsid assembly modulator QL-007 inhibits HBV replication and infection through altering capsid assembly","volume":"218","author":"Xi","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2025.118259_b0180","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.0c00346","article-title":"Discovery of phthalazinone derivatives as novel hepatitis B virus capsid inhibitors","volume":"63","author":"Chen","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118259_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1021\/acsinfecdis.6b00159","article-title":"Optimization and synthesis of pyridazinone derivatives as novel inhibitors of hepatitis B virus by inducing genome-free capsid formation","volume":"3","author":"Lu","year":"2017","journal-title":"ACS Infect Diseases"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:40:49Z","timestamp":1775097649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S0968089625002007"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118259","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118259"}}